Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Izzedine, H.
Right arrow Articles by Deray, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Izzedine, H.
Right arrow Articles by Deray, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2000) 15: 1102-1103
© 2000 European Renal Association-European Dialysis and Transplant Association

Letters

Indinavir pharmacokinetics in haemodialysis

H. Izzedine1, G. Aymard2, A. Hamani1, V. Launay-Vacher1 and G. Deray1

1 Department of Nephrology 2 Department of Pharmacology, Pitié-Salpêtrière Hospital, Paris, France

Sir,

Indinavir is a potent HIV-1 protease inhibitor which is frequently used as part of highly active antiretroviral therapy regimen. Since 10–20% of the dose is recovered in the urine as parent compound, it has been suggested that kidney function was not the major determinant of the elimination of . . . [Full Text of this Article]

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?